_id
6919efe53c536f8df231856c
Ticker
VAL.LSE
Name
ValiRx plc
Exchange
LSE
Address
Stonebridge House, England, United Kingdom, CM22 7BD
Country
UK
Sector
Healthcare
Industry
Biotechnology
Currency
GBX
Website
https://www.valirx.com
Description
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. It has an agreement with University of Dundee. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.
Last Close
3350
Volume
2859373
Current Price
0.385
Change
0
Last Updated
2025-12-30T11:42:46.710Z
Image
https://logo.clearbit.com/www.valirx.com
Ipo Date
-
Market Cap
2488115
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2024-12-31
Revenue
49775
Cost Of Revenue
132808
Gross Profit
-83033
Operating Expenses
1000589
Operating Income
-1083622
Interest Expense
1031
Pretax Income
-1078449
Net Income
-944785
Eps
-0.007137109571887646
Dividends Per Share
-
Shares Outstanding
742721072
Income Tax Expense
-75406
EBITDA
-914610
Operating Margin
-2177.0406830738325
Total Other Income Expense Net
5173
Cash
1555986
Short Term Investments
-
Receivables
102109
Inventories
69000
Total Current Assets
1896985
Property Plant Equipment
201662
Total Assets
4262106
Payables
147723
Short Term Debt
10472
Long Term Debt
1390
Total Liabilities
346413
Equity
4317382
Bs_currency_symbol
GBP
Depreciation
132808
Change In Working Capital
98437
Cash From Operations
-700734
Capital Expenditures
10246
Cash From Investing
19756
Cash From Financing
1427817
Net Change In Cash
746839
Cf_currency_symbol
-
PE
-
PB
11.80458920012174
ROE
-21.883284823997506
ROA
-22.167092981732505
FCF
-710980
Fcf Percent
-14.283877448518332
Piotroski FScore
1
Health Score
27
Deep Value Investing Score
4.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
2
Quality Investing Score
2.5
Value Investing Score
3
Quarters > 0 > quarter
2024-12-31
Quarters > 0 > income Statement > revenue
49775
Quarters > 0 > income Statement > cost Of Revenue
132808
Quarters > 0 > income Statement > gross Profit
-83033
Quarters > 0 > income Statement > operating Expenses
1000589
Quarters > 0 > income Statement > operating Income
-1083622
Quarters > 0 > income Statement > interest Expense
1031
Quarters > 0 > income Statement > pretax Income
-1078449
Quarters > 0 > income Statement > net Income
-944785
Quarters > 0 > income Statement > eps
-0.007137109571887646
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
132376418
Quarters > 0 > income Statement > income Tax Expense
-75406
Quarters > 0 > income Statement > EBITDA
-914610
Quarters > 0 > income Statement > operating Margin
-2177.0406830738325
Quarters > 0 > income Statement > total Other Income Expense Net
5173
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
1555986
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
102109
Quarters > 0 > balance Sheet > inventories
69000
Quarters > 0 > balance Sheet > total Current Assets
1896985
Quarters > 0 > balance Sheet > property Plant Equipment
201662
Quarters > 0 > balance Sheet > total Assets
4262106
Quarters > 0 > balance Sheet > payables
147723
Quarters > 0 > balance Sheet > short Term Debt
10472
Quarters > 0 > balance Sheet > long Term Debt
1390
Quarters > 0 > balance Sheet > total Liabilities
346413
Quarters > 0 > balance Sheet > equity
4317382
Quarters > 0 > balance Sheet > currency_symbol
GBP
Quarters > 0 > cash Flow > net Income
-944785
Quarters > 0 > cash Flow > depreciation
132808
Quarters > 0 > cash Flow > change In Working Capital
98437
Quarters > 0 > cash Flow > cash From Operations
-700734
Quarters > 0 > cash Flow > capital Expenditures
10246
Quarters > 0 > cash Flow > cash From Investing
19756
Quarters > 0 > cash Flow > cash From Financing
1427817
Quarters > 0 > cash Flow > net Change In Cash
746839
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.007137109571887646
Quarters > 0 > ratios > PB
11.80458920012174
Quarters > 0 > ratios > ROE
-21.883284823997506
Quarters > 0 > ratios > ROA
-22.167092981732505
Quarters > 0 > ratios > FCF
-710980
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-14.283877448518332
Quarters > 0 > health Score
27
Quarters > 1 > quarter
2024-06-30
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
134188
Quarters > 1 > income Statement > gross Profit
-134188
Quarters > 1 > income Statement > operating Expenses
953861
Quarters > 1 > income Statement > operating Income
-1088049
Quarters > 1 > income Statement > interest Expense
248
Quarters > 1 > income Statement > pretax Income
-1052006
Quarters > 1 > income Statement > net Income
-970908
Quarters > 1 > income Statement > eps
-0.007400568269626404
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
131193709
Quarters > 1 > income Statement > income Tax Expense
-52290
Quarters > 1 > income Statement > EBITDA
-917570
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
36043
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
809147
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
326653
Quarters > 1 > balance Sheet > inventories
69002
Quarters > 1 > balance Sheet > total Current Assets
1204802
Quarters > 1 > balance Sheet > property Plant Equipment
231901
Quarters > 1 > balance Sheet > total Assets
3692487
Quarters > 1 > balance Sheet > payables
170712
Quarters > 1 > balance Sheet > short Term Debt
10342
Quarters > 1 > balance Sheet > long Term Debt
6653
Quarters > 1 > balance Sheet > total Liabilities
187707
Quarters > 1 > balance Sheet > equity
3848211
Quarters > 1 > balance Sheet > currency_symbol
GBP
Quarters > 1 > cash Flow > net Income
-970908
Quarters > 1 > cash Flow > depreciation
134188
Quarters > 1 > cash Flow > change In Working Capital
14699
Quarters > 1 > cash Flow > cash From Operations
-884125
Quarters > 1 > cash Flow > capital Expenditures
27915
Quarters > 1 > cash Flow > cash From Investing
-57912
Quarters > 1 > cash Flow > cash From Financing
1576500
Quarters > 1 > cash Flow > net Change In Cash
634463
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.007400568269626404
Quarters > 1 > ratios > PB
13.125469982025415
Quarters > 1 > ratios > ROE
-25.230113421535354
Quarters > 1 > ratios > ROA
-26.294148090433357
Quarters > 1 > ratios > FCF
-912040
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2023-12-31
Quarters > 2 > income Statement > revenue
9600
Quarters > 2 > income Statement > cost Of Revenue
137423
Quarters > 2 > income Statement > gross Profit
-127823
Quarters > 2 > income Statement > operating Expenses
1019396
Quarters > 2 > income Statement > operating Income
-1147220
Quarters > 2 > income Statement > interest Expense
3414
Quarters > 2 > income Statement > pretax Income
-1150633
Quarters > 2 > income Statement > net Income
-1002277
Quarters > 2 > income Statement > eps
-0.009795551409939894
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
102319610
Quarters > 2 > income Statement > income Tax Expense
-85173
Quarters > 2 > income Statement > EBITDA
-1011236
Quarters > 2 > income Statement > operating Margin
-11950.208333333334
Quarters > 2 > income Statement > total Other Income Expense Net
-3413
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
174684
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
322791
Quarters > 2 > balance Sheet > inventories
69002
Quarters > 2 > balance Sheet > total Current Assets
566477
Quarters > 2 > balance Sheet > property Plant Equipment
242625
Quarters > 2 > balance Sheet > total Assets
3130438
Quarters > 2 > balance Sheet > payables
124637
Quarters > 2 > balance Sheet > short Term Debt
10213
Quarters > 2 > balance Sheet > long Term Debt
11857
Quarters > 2 > balance Sheet > total Liabilities
226511
Quarters > 2 > balance Sheet > equity
3218550
Quarters > 2 > balance Sheet > currency_symbol
GBP
Quarters > 2 > cash Flow > net Income
-1002277
Quarters > 2 > cash Flow > depreciation
135983
Quarters > 2 > cash Flow > change In Working Capital
134358
Quarters > 2 > cash Flow > cash From Operations
-667897
Quarters > 2 > cash Flow > capital Expenditures
2879
Quarters > 2 > cash Flow > cash From Investing
-2879
Quarters > 2 > cash Flow > cash From Financing
-45786
Quarters > 2 > cash Flow > net Change In Cash
-716562
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.009795551409939894
Quarters > 2 > ratios > PB
12.239377934162901
Quarters > 2 > ratios > ROE
-31.140637864877043
Quarters > 2 > ratios > ROA
-32.01714903793015
Quarters > 2 > ratios > FCF
-670776
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-69.8725
Quarters > 2 > health Score
27
Quarters > 3 > quarter
2023-06-30
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
118220
Quarters > 3 > income Statement > gross Profit
-118220
Quarters > 3 > income Statement > operating Expenses
1033099
Quarters > 3 > income Statement > operating Income
-1151320
Quarters > 3 > income Statement > interest Expense
1005
Quarters > 3 > income Statement > pretax Income
-1152325
Quarters > 3 > income Statement > net Income
-1035423
Quarters > 3 > income Statement > eps
-0.010271237578665377
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
100808008
Quarters > 3 > income Statement > income Tax Expense
-90000
Quarters > 3 > income Statement > EBITDA
-1033100
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-1005
Quarters > 3 > income Statement > currency_symbol
GBP
Quarters > 3 > balance Sheet > cash
891246
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
201368
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
1375285
Quarters > 3 > balance Sheet > property Plant Equipment
276446
Quarters > 3 > balance Sheet > total Assets
4072350
Quarters > 3 > balance Sheet > payables
90830
Quarters > 3 > balance Sheet > short Term Debt
12018
Quarters > 3 > balance Sheet > long Term Debt
16818
Quarters > 3 > balance Sheet > total Liabilities
119666
Quarters > 3 > balance Sheet > equity
4204124
Quarters > 3 > balance Sheet > currency_symbol
GBP
Quarters > 3 > cash Flow > net Income
-1035423
Quarters > 3 > cash Flow > depreciation
118220
Quarters > 3 > cash Flow > change In Working Capital
-88655
Quarters > 3 > cash Flow > cash From Operations
-1104454
Quarters > 3 > cash Flow > capital Expenditures
303302
Quarters > 3 > cash Flow > cash From Investing
-303302
Quarters > 3 > cash Flow > cash From Financing
1161525
Quarters > 3 > cash Flow > net Change In Cash
-246231
Quarters > 3 > cash Flow > currency_symbol
GBP
Quarters > 3 > ratios > PE
-0.010271237578665377
Quarters > 3 > ratios > PB
9.23166944647684
Quarters > 3 > ratios > ROE
-24.62874548895323
Quarters > 3 > ratios > ROA
-25.425687870639802
Quarters > 3 > ratios > FCF
-1407756
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
34
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
49775
Annuals > 0 > income Statement > cost Of Revenue
0
Annuals > 0 > income Statement > gross Profit
-217221
Annuals > 0 > income Statement > operating Expenses
2191446
Annuals > 0 > income Statement > operating Income
-2141671
Annuals > 0 > income Statement > interest Expense
1279
Annuals > 0 > income Statement > pretax Income
-2130455
Annuals > 0 > income Statement > net Income
-1915693
Annuals > 0 > income Statement > eps
-0.014537677807654019
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
131774347
Annuals > 0 > income Statement > income Tax Expense
-127696
Annuals > 0 > income Statement > EBITDA
-1862180
Annuals > 0 > income Statement > operating Margin
-4302.704168759417
Annuals > 0 > income Statement > total Other Income Expense Net
11216
Annuals > 0 > income Statement > currency_symbol
GBP
Annuals > 0 > balance Sheet > cash
1555986
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
102109
Annuals > 0 > balance Sheet > inventories
69000
Annuals > 0 > balance Sheet > total Current Assets
1896985
Annuals > 0 > balance Sheet > property Plant Equipment
201662
Annuals > 0 > balance Sheet > total Assets
4262106
Annuals > 0 > balance Sheet > payables
147723
Annuals > 0 > balance Sheet > short Term Debt
10472
Annuals > 0 > balance Sheet > long Term Debt
1390
Annuals > 0 > balance Sheet > total Liabilities
346413
Annuals > 0 > balance Sheet > equity
4317382
Annuals > 0 > balance Sheet > currency_symbol
GBP
Annuals > 0 > cash Flow > net Income
-2141671
Annuals > 0 > cash Flow > depreciation
266996
Annuals > 0 > cash Flow > change In Working Capital
143136
Annuals > 0 > cash Flow > cash From Operations
-1584859
Annuals > 0 > cash Flow > capital Expenditures
38156
Annuals > 0 > cash Flow > cash From Investing
-38156
Annuals > 0 > cash Flow > cash From Financing
3004317
Annuals > 0 > cash Flow > net Change In Cash
1381302
Annuals > 0 > cash Flow > currency_symbol
GBP
Annuals > 0 > ratios > PE
-0.014537677807654019
Annuals > 0 > ratios > PB
9.889068983935173
Annuals > 0 > ratios > ROE
-44.371635403121616
Annuals > 0 > ratios > ROA
-44.947098922457585
Annuals > 0 > ratios > FCF
-1623015
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-32.60703164239076
Annuals > 0 > health Score
26
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
9600
Annuals > 1 > income Statement > cost Of Revenue
255643
Annuals > 1 > income Statement > gross Profit
-246043
Annuals > 1 > income Statement > operating Expenses
2051667
Annuals > 1 > income Statement > operating Income
-2298539
Annuals > 1 > income Statement > interest Expense
4419
Annuals > 1 > income Statement > pretax Income
-2302958
Annuals > 1 > income Statement > net Income
-2037701
Annuals > 1 > income Statement > eps
-0.020062031886357492
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
101570021
Annuals > 1 > income Statement > income Tax Expense
-175173
Annuals > 1 > income Statement > EBITDA
-2044336
Annuals > 1 > income Statement > operating Margin
-23943.114583333336
Annuals > 1 > income Statement > total Other Income Expense Net
-4419
Annuals > 1 > income Statement > currency_symbol
GBP
Annuals > 1 > balance Sheet > cash
174684
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
99050
Annuals > 1 > balance Sheet > inventories
69002
Annuals > 1 > balance Sheet > total Current Assets
566477
Annuals > 1 > balance Sheet > property Plant Equipment
242625
Annuals > 1 > balance Sheet > total Assets
3130438
Annuals > 1 > balance Sheet > payables
124637
Annuals > 1 > balance Sheet > short Term Debt
10213
Annuals > 1 > balance Sheet > long Term Debt
11857
Annuals > 1 > balance Sheet > total Liabilities
226511
Annuals > 1 > balance Sheet > equity
3218550
Annuals > 1 > balance Sheet > currency_symbol
GBP
Annuals > 1 > cash Flow > net Income
-2298539
Annuals > 1 > cash Flow > depreciation
254203
Annuals > 1 > cash Flow > change In Working Capital
45703
Annuals > 1 > cash Flow > cash From Operations
-1772351
Annuals > 1 > cash Flow > capital Expenditures
306181
Annuals > 1 > cash Flow > cash From Investing
-306181
Annuals > 1 > cash Flow > cash From Financing
1115739
Annuals > 1 > cash Flow > net Change In Cash
-962793
Annuals > 1 > cash Flow > currency_symbol
GBP
Annuals > 1 > ratios > PE
-0.020062031886357492
Annuals > 1 > ratios > PB
10.22469335694645
Annuals > 1 > ratios > ROE
-63.31114943064423
Annuals > 1 > ratios > ROA
-65.09315948758608
Annuals > 1 > ratios > FCF
-2078532
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-216.51375
Annuals > 1 > health Score
26
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
224268
Annuals > 2 > income Statement > gross Profit
-224268
Annuals > 2 > income Statement > operating Expenses
2593379
Annuals > 2 > income Statement > operating Income
-2593379
Annuals > 2 > income Statement > interest Expense
5456
Annuals > 2 > income Statement > pretax Income
-2598835
Annuals > 2 > income Statement > net Income
-2406164
Annuals > 2 > income Statement > eps
-0.031126843253624723
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
77301896
Annuals > 2 > income Statement > income Tax Expense
-192671
Annuals > 2 > income Statement > EBITDA
-2369114
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-5456
Annuals > 2 > income Statement > currency_symbol
GBP
Annuals > 2 > balance Sheet > cash
1137477
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
326486
Annuals > 2 > balance Sheet > inventories
0
Annuals > 2 > balance Sheet > total Current Assets
1463963
Annuals > 2 > balance Sheet > property Plant Equipment
5561
Annuals > 2 > balance Sheet > total Assets
3975946
Annuals > 2 > balance Sheet > payables
24955
Annuals > 2 > balance Sheet > short Term Debt
15642
Annuals > 2 > balance Sheet > long Term Debt
22070
Annuals > 2 > balance Sheet > total Liabilities
149645
Annuals > 2 > balance Sheet > equity
4050840
Annuals > 2 > balance Sheet > currency_symbol
GBP
Annuals > 2 > cash Flow > net Income
-2593379
Annuals > 2 > cash Flow > depreciation
211933
Annuals > 2 > cash Flow > change In Working Capital
212
Annuals > 2 > cash Flow > cash From Operations
-1712245
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
2256050
Annuals > 2 > cash Flow > net Change In Cash
543805
Annuals > 2 > cash Flow > currency_symbol
GBP
Annuals > 2 > ratios > PE
-0.031126843253624723
Annuals > 2 > ratios > PB
6.1828693071066745
Annuals > 2 > ratios > ROE
-59.39913696912246
Annuals > 2 > ratios > ROA
-60.51802514420468
Annuals > 2 > ratios > FCF
-1712245
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
26
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
228789
Annuals > 3 > income Statement > gross Profit
-228789
Annuals > 3 > income Statement > operating Expenses
1677839
Annuals > 3 > income Statement > operating Income
-1677839
Annuals > 3 > income Statement > interest Expense
2765
Annuals > 3 > income Statement > pretax Income
-1680604
Annuals > 3 > income Statement > net Income
-1547191
Annuals > 3 > income Statement > eps
-0.02380112335125458
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
65004957
Annuals > 3 > income Statement > income Tax Expense
-133413
Annuals > 3 > income Statement > EBITDA
-1449051
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-2765
Annuals > 3 > income Statement > currency_symbol
GBP
Annuals > 3 > balance Sheet > cash
593672
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
206338
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
800010
Annuals > 3 > balance Sheet > property Plant Equipment
13278
Annuals > 3 > balance Sheet > total Assets
3523926
Annuals > 3 > balance Sheet > payables
13056
Annuals > 3 > balance Sheet > short Term Debt
17385
Annuals > 3 > balance Sheet > long Term Debt
35654
Annuals > 3 > balance Sheet > total Liabilities
109555
Annuals > 3 > balance Sheet > equity
3599238
Annuals > 3 > balance Sheet > currency_symbol
GBP
Annuals > 3 > cash Flow > net Income
-1677839
Annuals > 3 > cash Flow > depreciation
228789
Annuals > 3 > cash Flow > change In Working Capital
-66697
Annuals > 3 > cash Flow > cash From Operations
-1260572
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
7343
Annuals > 3 > cash Flow > net Change In Cash
-1253229
Annuals > 3 > cash Flow > currency_symbol
GBP
Annuals > 3 > ratios > PE
-0.02380112335125458
Annuals > 3 > ratios > PB
5.85168473660258
Annuals > 3 > ratios > ROE
-42.986626613744356
Annuals > 3 > ratios > ROA
-43.90532037278876
Annuals > 3 > ratios > FCF
-1260572
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
29
Valuation > metrics > PE
-0.007137109571887646
Valuation > metrics > PB
11.80458920012174
Valuation > final Score
20
Valuation > verdict
293.5% Overvalued
Profitability > metrics > ROE
-21.883284823997506
Profitability > metrics > ROA
-49.8045582859116
Profitability > metrics > Net Margin
-18.981115017579107
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.08023681944289386
Risk > metrics > Interest Coverage
-1051.0397672162949
Risk > final Score
-4144
Risk > verdict
High
Liquidity > metrics > Current Ratio
11.99143462182749
Liquidity > metrics > Quick Ratio
11.555264072821517
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
15
Prev Profitabilities > 1
0
Prev Profitabilities > 2
15
Prev Risks > 0
-17489
Prev Risks > 1
-1284
Prev Risks > 2
-4522
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:04:44.880Z
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. It has an agreement with University of Dundee. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.
Stock Price
GBp 0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AUK's January 2026 Stocks That Might Be Trading Below Fair Value simplywall.st
Read more →UK Blue-Chip Stock Sees Significant Shift on FTSE 100 Index Live Kalkine Media
Read more →Showing 2 of 10
(Last Updated 2024-12-31)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of ValiRx plc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2024-12-31)
(Last Updated 2024-12-31)
Revenue
£ 0
Cost Of Revenue
£ 0
Gross Profit
£ 0
Operating Expenses
£ 0
Operating Income
£ 0
Interest Expense
£ 0
Pretax Income
£ 0
Net Income
£ 0
Income Tax Expense
£ 0
EBITDA
£ 0
Total Other Income Expense Net
£ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2024-12-31)
Cash
£ 0
Short Term Investments
£ 0
Receivables
£ 0
Inventories
£ 0
Total Current Assets
£ 0
Property Plant Equipment
£ 0
Total Assets
£ 0
Payables
£ 0
Short Term Debt
£ 0
Long Term Debt
£ 0
Total Liabilities
£ 0
Equity
£ 0
(Last Updated 2024-12-31)
Net Income
£ 0
Depreciation
£ 0
Change In Working Capital
£ 0
Cash From Operations
£ 0
Capital Expenditures
£ 0
Cash From Investing
£ 0
Cash From Financing
£ 0
Net Change In Cash
£ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.